Meningococcal Vaccines Offers Excellent Defence Against Four Meningococcal Bacterial Types

 

Meningococcal Vaccines

Meningococcal Vaccines are a type of immunization used to protect against meningococcal disease. This disease is caused by the bacteria Neisseria meningitidis, which can cause severe infections in the lining of the brain and spinal cord, as well as bloodstream infections. Meningococcal disease can be fatal or cause long-term complications, such as brain damage, hearing loss, and limb amputations.

There are several types of Meningococcal Vaccines available, including conjugate vaccines, polysaccharide vaccines, and combination vaccines. Conjugate vaccines are the most commonly used type and provide protection against four strains of the bacteria: A, C, W, and Y. Polysaccharide vaccines provide protection against the same strains but are less effective and are typically only recommended for people over the age of 55. Combination vaccines provide protection against meningococcal disease as well as other diseases, such as diphtheria, tetanus, and pertussis.

According To Coherent Market Insights, The Global Meningococcal Vaccines Market Is Estimated To Account For US$ 3,341.9 Mn In Terms Of Value And Is Expected To Reach US$ 7,732.3 Mn By The End Of 2027.

Meningococcal Vaccines are typically given in two doses, with the second dose administered several months after the first. Booster doses may also be recommended for certain populations, such as people who are traveling to areas where meningococcal disease is more common or people with weakened immune systems.

The timing of vaccination is important for ensuring adequate protection against meningococcal disease. Adolescents and young adults are at an increased risk for Meningococcal Disease, with most cases occurring in people between the ages of 15 and 24. As a result, the Centers for Disease Control and Prevention (CDC) recommends routine vaccination for adolescents starting at age 11-12, with a booster dose at age 16. College students, particularly those living in dormitories, are also at an increased risk for meningococcal disease and should receive the Vaccines.

Comments

Popular posts from this blog

The Future Of Solar Energy: Advancements In Thin Film Solar Cell Technology

Cross Linked Polyethylene Market Growth Accelerated by Increasing demand from pipe and cables application

Gastroesophageal Reflux Disease (GERD) Treatment Devices Market is expanding rapidly with Ethicon introducing LINX Reflux Management System to provide effective long-term control over GERD